0001225208-18-000493.txt : 20180103 0001225208-18-000493.hdr.sgml : 20180103 20180103195319 ACCESSION NUMBER: 0001225208-18-000493 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20171229 FILED AS OF DATE: 20180103 DATE AS OF CHANGE: 20180103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Phalen Michael P. CENTRAL INDEX KEY: 0001483882 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 18508002 MAIL ADDRESS: STREET 1: C/O BOSTON SCIENTIFIC STREET 2: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 4 1 doc4.xml X0306 4 2017-12-29 0000885725 BOSTON SCIENTIFIC CORP BSX 0001483882 Phalen Michael P. 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 1 EVP & President, MedSurg Common Stock 2017-12-29 4 M 0 15835.0000 7.1600 A 113745.0000 D Common Stock 2017-12-29 4 S 0 15835.0000 25.2520 D 97910.0000 D Common Stock 2018-01-01 4 M 0 13341.0000 0.0000 A 111251.0000 D Common Stock 2018-01-01 4 F 0 4578.0000 24.7900 D 106673.0000 D Stock Option (Right to Buy) 7.1600 2017-12-29 4 M 0 15835.0000 0.0000 D 2021-02-28 Common Stock 15835.0000 0.0000 D Performance Share Units 2018-01-01 4 M 0 13341.0000 0.0000 D 2017-12-31 2017-12-31 Common Stock 13341.0000 0.0000 D This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.24 to $25.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the date of grant. Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. phalenpoa.txt /s/ Vance R. Brown, Attorney-in-fact 2018-01-03 EX-24 2 phalenpoa.txt POWER OF ATTORNEY Know all by these present that the undersigned hereby constitutes and appoints each of Desiree Ralls-Morrison, Vance R. Brown, Jeff Mann, Ashley E. McGrane and Mai-KhoiNguyen-Thanh signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer and/or director of Boston Scientific Corporation (the "Company"), Forms 3, 4 and 5, and amendments thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer and/or director of the Company, Forms 144 in accordance with Rule 144 of the Securities Exchange Act of 1933, as amended and the rules and regulations thereunder; and (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 or Rule 144 of the Securities Act of 1933, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 and Forms 144 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 2nd day of January, 2018. /s/ Michael P. Phalen ________________ Michael P. Phalen